SUMMARY -Notalgia paresthetica is a common, although under-recognized condition characterized by localized chronic pruritus in the upper back, most often aff ecting middle-aged women. Apart from pruritus, patients may present with a burning or cold sensation, tingling, surface numbness, tenderness and foreign body sensation. Additionally, patients often present with hyperpigmented skin at the site of symptoms. Th e etiology of this condition is still poorly understood, although a number of hypotheses have been described. It is widely accepted that notalgia paresthetica is a sensory neuropathy caused by alteration and damage to posterior rami of thoracic spinal nerves T2 through T6. To date, no well-defi ned treatment has been found, although many treatment modalities have been reported with varying success, usually providing only temporary relief.
Introduction
Notalgia paresthetica (NP) is a common, yet seldom reported condition characterized by chronic pruritus in the interscapular and paravertebral region with periodic remissions and exacerbations. Th e disease was fi rst described by the Russian neurologist Astwazaturow in 1934. Analogous to meralgia paresthetica or cheiralgia paresthetica, the name of the disorder is derived from the ancient Greek words noton, "back" and algia, "pain" [1] [2] [3] . Th e disease primarily aff ects adults, more frequently women than men 4 , however, some hereditary cases have been reported in younger patients (even 6-yearold children) when it is associated with multiple endocrine neoplasia type 2A (MEN 2A) 5 .
Etiology
Th e exact etiology of NP still has not been fully elucidated, however, it is widely accepted that NP is a sensory neuropathy caused by alteration and damage to the cutaneous branches of the dorsal primary rami of thoracic spinal nerves, most commonly T2 through T6. Th e posterior rami of spinal nerves T2 through T6 are anatomically unique in that they pass through the multifi dus spinae muscle at a right-angle (90-degree) course en route to the epidermis, and therefore may be more susceptible to injury, which is why Massey and Pleet, as well as Pećina et al. suggested nerve entrapment as the underlying cause of NP ( Fig. 1) 2,3 . Th e damage to spinal nerves may be caused by impingement from degenerative changes in the spine (for example, osteoarthritic changes, kyphosis, vertebral hyperostosis) or compression by muscle fi bers [6] [7] [8] . Unfortunately, typically there is no strong correlation between spinal pathology demonstrated on imaging studies and the dermatomal localization of symptoms in patients with NP 9 . Furthermore, increased dermal innervation, various viscerocutaneous refl ex mechanisms, neurotoxicity of certain chemicals and hereditary susceptibility to peripheral neuropathy have also been implicated in the pathophysiology of NP 2, 6, [10] [11] [12] [13] . In patients with MEN 2A, the etiology appears to diff er and an association with the codon 634 RET mutation has been reported in the literature 5, 7 .
Clinical Presentation
Patients with NP typically present with intermittent, paroxysmal pruritus, which tends to vary in intensity, and is often accompanied by pain, hyperesthesia and various paresthesias including burning, as well as cold sensation, tingling, surface numbness, tenderness and foreign body sensation. Th ese sensations are usually felt medially or inferior to the scapula and lateral to the thoracic spine. Th e disorder is typically unilateral, however, interscapular and bilateral distribution of symptoms has also been reported 6, 14 . Th ere are usually no known triggering or alleviating factors, although one review in the literature suggests that patients with MEN 2A demonstrate amelioration of symptoms following exposure to sunlight 7 . A typical dermatologic fi nding is hyperpigmentation of the aff ected area with irregular and indistinct borders with occasional keratotic or atrophic surfaces; it has been reported in two-thirds of published cases in the literature (Fig. 2) 6 . Th is skin manifestation is believed to be a result of chronic scratching and rubbing or, as other authors have suggested, a consequence of neurogenic release of substance P into the skin, which not only leads to pruritus, but also causes proliferation of epidermal cells, arterial smooth muscle cells and fibroblasts 15, 16 .
Diagnosis
Th e diagnosis of NP is most frequently made on the basis of reported symptoms and specifi c area affected. Physical examination and detailed medical history regarding vertebral and thoracic trauma, degenerative disorders or malignancies, vertebral fracture, cervical disc disease, osteoarthritis and familial history should be obtained, while in certain cases imaging methods may be considered 4, 6, 7, 17 . Since NP can be an early manifestation of MEN 2A, in younger patients a blood test to check the level of calcitonin should be performed as a screening method for medullary thyroid carcinoma 6, 7, 18 . In addition, other more common pruritic diseases such as pigmented contact dermatitis, pityrosporum folliculitis, parapsoriasis, neurodermatitis and primitive cutaneous amyloidosis should be excluded prior to 0.025% cream 5 x daily for 1 week, followed by 3 x daily for 5 weeks: 70% of patients reported improvement, however, most experienced relapse within a month after treatment; 8% patches: 3 patients experienced immediate relief of itch, duration varied considerably Tacrolimus   21 0.1% ointment twice daily: reduction in both intensity and frequency of itch was reported in 5 of 7 patients after 6 weeks of treatment, a tolerable burning sensation was the only side eff ect reported, symptoms generally returned after discontinuation of treatment Anesthetics 22 Lidocaine and prilocaine cream under occlusion 2 x daily: complete resolution of symptoms in 2 out of 3 patients, the eff ect was not maintained after stopping treatment Intralesional Botulinum toxin A [23] [24] [25] 4 U per superfi cial injection, spaced 2 cm apart: 16 U in one patient, 72 U in another patient led to resolution of pruritus and decrease of hyperpigmentation for over 18 months; another study in 5 patients and later a randomized, placebo-controlled, double-blind clinical trial in 20 patients failed to replicate these results Corticosteroids 26 Triamcinolone 2.5 mg/mL: success in treatment of 2 patients Oral Oxcarbazepine 27 6-month treatment, initial dose of 300 mg twice daily and increased to 600 mg twice daily or 900 mg twice daily to achieve adequate relief: alleviation of symptoms in 4 out of 5 patients, 1 patient withdrew due to side eff ects (dizziness and headache) Gabapentin 28, 29 Initiated at a dose of 300 mg at night and increased to 600 mg at night: resulted in absolute resolution of pruritus in 1 patient, after discontinuation of treatment, pruritus returned; 300 mg/day for 4 weeks: improvement in itching observed in all patients, side eff ects (mild gastric discomfort, dizziness) were well tolerated Amitriptyline 30 10 mg daily for 9 months: satisfactory reduction of pruritus in 1 patient, sustained for at least 1 month after stopping treatment Other Surgery 31 Surgical decompression of the cutaneous nerve: resolution of pruritus for at least 4 months in 1 patient Nerve block 32 Local anesthetic block in 1 patient using 5 mL of 0.75% bupivacaine combined with 40 mg of methylprednisolone acetate achieved disappearance of symptoms for over 1 year TENS 33 5 sessions a week for 2 weeks, 50-100 Hz, 20 min duration, 40-75 μs pulse width: mostly mild amelioration of itch was attained in a group of 15 patients EMS 15 30 seconds on and 30 seconds off for 15 minutes twice daily, 70 Hz with a pulse width of 300 μs: relief of pain beginning within days upon starting EMS, recurrence of pain after discontinuation of stimulation for a prolonged period of time, maintenance of analgesic eff ects with only intermittent stimulation in 4 cases of NP with injury to the long thoracic nerve Narrow band UV-B Deep intramuscular stimulation acupuncture to the paravertebral muscles in the aff ected area, 2-6 treatments: in 16 patients, absolute or partial alleviation of pruritus was observed, relapse occurred within 1-12 months Exercise 36 Stretching and strengthening exercises that elongate the spine and strengthen postural muscles: resolution of symptoms in 2 patients Physiotherapy 6 Spinal and paraspinal physiotherapy (ultrasound, radiation, multimodal physiotherapy): 4 of 6 patients showed improvement of symptoms that lasted for 1-9 years TENS = transcutaneous electrical nerve stimulation; EMS = electrical muscle stimulation diagnosing a patient with NP, which is commonly a clinical diagnosis of exclusion 6 .
Treatment
Management of NP is diffi cult and still presents a clinical challenge, as the condition is often resistant to multiple therapies. Just as the pathogenesis of NP remains unclear, there is no well-defi ned treatment, although numerous treatment modalities have been reported, with variable results. Conventional antipruritic therapies such as antihistamines and topical corticosteroids do not address the neuropathic origin of NP and show poor eff ect 6 . Potential treatment includes topical anesthetics, capsaicin and tacrolimus, intralesional corticosteroids, cutaneous botulinum toxin type A injections, gabapentin, oxcarbazepine, amitriptyline, surgical decompression, paravertebral local anesthetic blocks, transcutaneous electrical nerve stimulation (TENS), electrical muscle stimulation (EMS), exposure to narrow band UV-B radiation, spinal manipulation, physical therapy applications, osteopathic manipulative treatment and acupuncture ( Table 1) . Most of these therapeutic options have been described in a small number of patients and with varying degrees of success.
Conclusion
Th ere are fewer than 100 cases of NP described in the scientifi c literature to date. Although it is not a severe disorder per se, the lack of effi cient treatment and understanding of the condition greatly aff ects patient quality of life. Th erefore, further research regarding the underlying pathophysiology is of great importance in order to appropriately manage and treat NP patients.
